Novelix Pharmaceuticals Ltd
Incorporated in 1994, Trimurthi Ltd is in the business of Pharmaceutical distribution and Retail pharmacy[1]
- Market Cap ₹ 73.2 Cr.
- Current Price ₹ 29.3
- High / Low ₹ 29.3 / 18.9
- Stock P/E 915
- Book Value ₹ 7.03
- Dividend Yield 0.00 %
- ROCE 0.96 %
- ROE 0.64 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 4.17 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 0.00% over last 3 years.
- Company has high debtors of 216 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Consumer Discretionary Consumer Services Retailing Pharmacy Retail
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
5.76 | 1.46 | 1.01 | 3.65 | 3.12 | 3.61 | 1.50 | 1.31 | 1.14 | 1.92 | 4.49 | 30.72 | |
4.86 | 0.98 | 0.58 | 3.45 | 2.64 | 3.41 | 1.32 | 4.50 | 2.86 | 1.92 | 4.47 | 30.58 | |
Operating Profit | 0.90 | 0.48 | 0.43 | 0.20 | 0.48 | 0.20 | 0.18 | -3.19 | -1.72 | 0.00 | 0.02 | 0.14 |
OPM % | 15.62% | 32.88% | 42.57% | 5.48% | 15.38% | 5.54% | 12.00% | -243.51% | -150.88% | 0.00% | 0.45% | 0.46% |
0.00 | 0.00 | 0.04 | 0.13 | -0.04 | 0.11 | 0.00 | 0.00 | 0.23 | 0.00 | 0.04 | 0.02 | |
Interest | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.29 | 0.40 | 0.34 | 0.12 | 0.15 | 0.12 | 0.08 | 0.08 | 0.07 | 0.06 | 0.04 | 0.04 |
Profit before tax | 0.60 | 0.08 | 0.13 | 0.21 | 0.29 | 0.19 | 0.10 | -3.27 | -1.56 | -0.06 | 0.02 | 0.12 |
Tax % | 31.67% | 87.50% | 30.77% | 23.81% | 34.48% | -31.58% | 20.00% | 0.00% | -0.64% | 0.00% | 50.00% | 33.33% |
0.42 | 0.02 | 0.10 | 0.15 | 0.18 | 0.25 | 0.09 | -3.27 | -1.56 | -0.06 | 0.01 | 0.08 | |
EPS in Rs | 0.52 | 0.02 | 0.12 | 0.19 | 0.22 | 0.31 | 0.11 | -4.04 | -1.93 | -0.07 | 0.01 | 0.03 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 36% |
5 Years: | 83% |
3 Years: | 200% |
TTM: | 584% |
Compounded Profit Growth | |
---|---|
10 Years: | 15% |
5 Years: | -2% |
3 Years: | 27% |
TTM: | 500% |
Stock Price CAGR | |
---|---|
10 Years: | 13% |
5 Years: | 73% |
3 Years: | 53% |
1 Year: | 55% |
Return on Equity | |
---|---|
10 Years: | -4% |
5 Years: | -11% |
3 Years: | 0% |
Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 9.95 |
Reserves | 3.35 | 3.24 | 3.34 | 3.49 | 3.72 | 3.91 | 3.97 | 0.70 | -0.86 | -0.90 | -0.75 | 7.59 |
0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
0.45 | 0.26 | 0.19 | 0.15 | 0.44 | 0.18 | 0.02 | 0.02 | 0.01 | 0.06 | 0.01 | 9.67 | |
Total Liabilities | 11.94 | 11.60 | 11.63 | 11.74 | 12.26 | 12.19 | 12.09 | 8.82 | 7.25 | 7.26 | 7.36 | 27.21 |
1.17 | 0.75 | 0.55 | 0.59 | 0.61 | 0.37 | 0.31 | 0.22 | 1.96 | 0.17 | 0.12 | 0.19 | |
CWIP | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.32 | 1.40 | 3.01 | 1.84 | 2.92 | 2.72 | 3.53 | 3.64 | 0.59 | 2.78 | 3.06 | 0.04 |
10.45 | 9.45 | 7.99 | 9.31 | 8.73 | 9.10 | 8.25 | 4.96 | 4.70 | 4.31 | 4.18 | 26.98 | |
Total Assets | 11.94 | 11.60 | 11.63 | 11.74 | 12.26 | 12.19 | 12.09 | 8.82 | 7.25 | 7.26 | 7.36 | 27.21 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.03 | -0.43 | 2.03 | -1.07 | 1.08 | -0.44 | 1.21 | 0.58 | 0.59 | -2.41 | -0.34 | -13.68 | |
0.50 | -0.25 | -1.76 | 0.97 | -1.27 | 0.45 | -0.42 | 0.21 | 0.28 | 0.08 | 0.19 | 2.93 | |
-0.03 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.31 | |
Net Cash Flow | 0.50 | -0.69 | 0.27 | -0.10 | -0.19 | 0.01 | 0.79 | 0.78 | 0.87 | -2.33 | -0.16 | 0.56 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 53.86 | 30.00 | 3.61 | 40.00 | 129.86 | 216.37 | 19.47 | 25.08 | 32.02 | 36.12 | 0.81 | 215.53 |
Inventory Days | 27.55 | 0.00 | 28.18 | 19.03 | 13.18 | 38.93 | 89.46 | 238.83 | 221.70 | 113.11 | 10.37 | |
Days Payable | 4.30 | 0.00 | 53.63 | 13.18 | 4.87 | 3.58 | 0.00 | 13.52 | 0.00 | 114.80 | ||
Cash Conversion Cycle | 77.11 | 30.00 | 3.61 | 68.18 | 95.26 | 216.37 | 53.53 | 110.96 | 270.84 | 244.30 | 113.92 | 111.10 |
Working Capital Days | 570.95 | 2,225.00 | 2,583.91 | 863.00 | 932.39 | 858.41 | 1,710.63 | 819.16 | 646.75 | 743.31 | 325.17 | 197.00 |
ROCE % | 5.40% | 0.70% | 0.79% | 0.69% | 2.82% | 0.67% | 0.83% | -31.34% | -19.20% | -0.83% | -0.27% | 0.96% |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Novelix exempt from Annual Secretarial Compliance Report for FY 2024-25 under SEBI Regulation 24A.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
29 May - Submission of newspaper publication of extract of financial results for the quarter ended 31st March, 2025.
-
Intimation Of Appointment Of Internal Auditor.
27 May - Appointment of M/s VRPS & Co. as internal auditor for FY 2025-26 approved by board on 27 May 2025.
-
Intimation Of Appointment Of Secretarial Auditor.
27 May - Appointment of M/s Khushbu Kanwar & Co. as Secretarial Auditor for five years from April 2025.
-
Results- Financial Results For March 31, 2025
27 May - Novelix Pharmaceuticals reports audited standalone financials for FY ended March 31, 2025 with profit of Rs 8.45 lakh.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Services Offered:[1]
a) Trading and distribution of food products
b) Investments and trading of shares
c) Investments in land and properties